Overview of Dr. Gomez
Dr. Daniel Gomez is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of California (San Francisco) School of Medicine and has been in practice 16 years. He is one of 106 doctors at Memorial Sloan Kettering Cancer Center and one of 26 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Radiation Oncology. He has more than 100 publications and over 500 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
- Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2005 - 2009
- University of California San Francisco School of MedicineClass of 2004
Certifications & Licensure
- FL State Medical License 2023 - Present
- NY State Medical License 2005 - 2026
- NJ State Medical License 2019 - 2025
- TX State Medical License 2009 - 2020
- American Board of Radiology Radiation Oncology
Clinical Trials
- A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2022 Jun 15
Roles: Contact, Principal Investigator
- Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study Start of enrollment: 2018 Jan 17
Roles: Principal Investigator, Contact
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2022 Dec 09
Roles: Contact
Publications & Presentations
PubMed
- Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with SRS.Benjamin Gaeta, Jordan E Eichholz, Henry Walch, Ahmet Turan Ilica, Lillian Boe
International Journal of Radiation Oncology, Biology, Physics. 2025-02-08 - Management of oligoprogressive and oligopersistent disease in advanced NSCLC.Revathi Ravella, Erin Jay G Feliciano, Edward Christopher Dee, Daniel R Gomez, Puneeth Iyengar
Clinical Advances in Hematology & Oncology. 2025-02-05 - Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer.Matthew T McMillan, Annemarie Shepherd, Alissa J Cooper, Adam J Schoenfeld, Abraham J Wu
Radiotherapy and Oncology. 2025-02-01
Press Mentions
- Plenary 2 Explores Definitions, Treatment Modalities for Oligometastatic DiseaseAugust 8th, 2022
- Radiation Oncology Appointments Plummeted in the COVID-19 Pandemic—but Seem to Be Rising AgainMay 29th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: